cystic fibrosis

An enzyme produced using computer design, in combination with the antibiotic tobramycin, efficiently kills Pseudomonas aeruginosa, a pathogen that often infects the lungs of patients with cystic fibrosis (CF), a study shows. It works to neutralize a metabolite called pyocyanin, required by P. aeruginosa to attach to surfaces…

Bronchitol (mannitol), an inhaled mucus-clearing treatment for cystic fibrosis (CF), is now commercially available in the U.S., according to Chiesi USA, which is marketing the therapy in the country. “We are excited to bring the first dry powder inhaled mucoactive agent to the U.S. for adults with CF,…

Thanks to the Cystic Fibrosis Foundation (CFF), people with cystic fibrosis (CF) in the United States will receive free access to the online wellness and exercise platform Beam through the end of this year. “Wellness plays a critical role in an individual’s quality of life no matter what challenges…

Two bacterial species known to be frequent sources of lung infection in people with cystic fibrosis (CF) — Pseudomonas aeruginosa and Staphylococcus aureus — can feed each other with a nutrient called purine that both need to thrive, a study shows. Such interaction could determine the course of…

Pel, a complex sugar molecule produced by Pseudomonas aeruginosa, contributes to the bacterium’s ability to aggregate and resist both antibiotics and mucus thinners in people with cystic fibrosis (CF) by binding to an abundant component of their thick mucus, a study reports. These findings shed light on the underlying mechanisms of the…

The Cystic Fibrosis Foundation has given an additional $1.8 million to support early toxicology studies of pravibismane, Microbion’s investigational inhaled therapy for lung infections in people with cystic fibrosis (CF).  Data from these early toxicology studies, expected to conclude by mid-year, could support regulatory requests to…

A rare and disease-causing mutation for cystic fibrosis (CF), called the F1099L mutation and characterized by a protein maturation defect, was identified in a recent study. Treatment with lumacaftor was also seen to effectively rescue function of the defective CFTR protein that results from this mutation, found in two infants…

Work targeting new therapies against antibiotic-resistant infections, led by West Virginia University (WVU) researchers, received a $1.4 million grant from a branch of the U.S. Department of Defense (DOD). The grant, awarded by the Defense Threat Reduction Agency, will be used to identify the best combinations of antibodies and…

The Cystic Fibrosis Foundation (CFF) has given Beyond Air up to $2.17 million to test its portable inhaled nitric oxide therapy for people with cystic fibrosis (CF) who have chronic, treatment-resistant lung infections caused by non-tuberculous mycobacteria (NTM). This grant award will support a pilot clinical trial to determine…

Researchers have developed a patient-derived model of cystic fibrosis (CF) to better understand whether these patients are more susceptible to COVID-19 infection and its associated serious complications. The project is being led by Ruobing “Ruby” Wang, MD, who cares for CF patients in the division of pulmonary medicine…